Payment overview · 2025
General Payments
$524.87
29 reported records · 15 companies
Healthcare provider profile · identity verified
Charles C. Smith Iii, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ORLEANS, LA · NPI 1366493025
Verified facts
What the public records show
CMS Open Payments records show Charles C. Smith Iii, M.D. received $524.87 in general payments during 2025 across 29 reported records.
Amgen Inc. accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.73 | 17.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.64 | 12.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.43 | 10.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.78 | 9.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.06 | 7.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $33.96 | 6.5% | 2 | 2025 |
| Pinnacle Biologics, Inc | Unresolved — no canonical attribution shown | $32.27 | 6.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.00 | 5.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $21.08 | 4.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $19.69 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.59 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.46 | 3.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.93 | 3.2% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $15.64 | 3.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.61 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $524.87 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.73 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.78 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.39 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| Photofrin Normalized: photofrin |
Drug | Pinnacle Biologics, Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 176 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 128 |
| Losartan Potassium | Losartan Potassium | 360 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 220 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 44 |
| Alprazolam | Alprazolam | 187 | 43 |
| Eliquis | Apixaban | 176 | 32 |
| Lorazepam | Lorazepam | 153 | 34 |
| Gabapentin | Gabapentin | 143 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 49 |
| Metformin Hcl | Metformin Hcl | 123 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 38 |
| Famotidine | Famotidine | 94 | 29 |
| Allopurinol | Allopurinol | 91 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 90 | 33 |
| Prednisone | Prednisone | 90 | 40 |
| Jardiance | Empagliflozin | 89 | 25 |
| Tramadol Hcl | Tramadol Hcl | 88 | 23 |
| Memantine Hcl | Memantine Hcl | 85 | 19 |
| Montelukast Sodium | Montelukast Sodium | 83 | 24 |
| Synthroid | Levothyroxine Sodium | 83 | 20 |
| Azithromycin | Azithromycin | 80 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 22 |
| Furosemide | Furosemide | 77 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 19 |
| Trazodone Hcl | Trazodone Hcl | 71 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 69 | 12 |
| Cephalexin | Cephalexin | 68 | 39 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 15 |
| Lisinopril | Lisinopril | 65 | 17 |
| Mounjaro | Tirzepatide | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 14 |
| Repatha Sureclick | Evolocumab | 62 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 21 |
| Carvedilol | Carvedilol | 57 | 16 |
| Simvastatin | Simvastatin | 55 | 12 |
| Valsartan | Valsartan | 54 | 15 |
| Fentanyl | Fentanyl | 52 | suppressed |
| Irbesartan | Irbesartan | 52 | 16 |
| Diazepam | Diazepam | 51 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | suppressed |
| Temazepam | Temazepam | 49 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 48 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 35 |
| Finasteride | Finasteride | 43 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 18 |
| Ozempic | Semaglutide | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | 15 |
| Clonazepam | Clonazepam | 41 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 13 |
| Meloxicam | Meloxicam | 41 | 17 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Omeprazole | Omeprazole | 39 | 16 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 28 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 19 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 14 |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Cefdinir | Cefdinir | 27 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 16 |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 18 |
| Fluconazole | Fluconazole | 24 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 15 |
| Rytary | Carbidopa/Levodopa | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $524.87 · 29 records | Amgen Inc. | ABRYSVO, Arikayce, BREZTRI, COMIRNATY, Cleerly Ischemia, Cleerly Labs, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, JARDIANCE, LEQVIO, NUCALA, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, Photofrin, REPATHA, XYOSTED, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error